Side-by-side · Research reference

CardiogenvsChonluten

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-MechanisticHUMAN-REVIEWED8/38 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

01Mechanism of Action

Parameter

Cardiogen

Chonluten

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Chonluten

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Once or twice daily

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

In vitro mechanistic

Route

Subcutaneous injection

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

Typical protocol dose

—

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

Clinical validation

—

None (PubMed indexed)

04Side Effects & Safety

Parameter

Cardiogen

Chonluten

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Documented adverse events

—

No published safety data in PubMed-indexed literature

Theoretical risks

—

Peptide hypersensitivity, GI intolerance (uncharacterized)

Drug interactions

—

Unknown — no pharmacokinetic studies available

Pregnancy / lactation

—

No data — avoid

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Chonluten

·Known hypersensitivity to peptide components

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

05Administration Protocol

Parameter

Cardiogen

Chonluten

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

3. Timing

Variable — often evening injection. No established circadian preference.

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Chonluten

— no documented stacks